Semble, a healthcare management platform serving outpatient providers, has raised £30 million in a Series C funding round to scale its operations across the UK and Europe.

The company was founded to address a well-documented problem in outpatient care: the inability of disconnected software systems to communicate with one another. Clinics and healthcare groups have long relied on separate tools for scheduling, patient records, billing and communications, with no single platform connecting these functions. Semble positions itself as that connective layer, managing each stage of the patient journey from referral through to follow-up. Its clients range from sole practitioners to large enterprise healthcare organisations.

The funding round arrives at a time when outpatient providers are under considerable operational strain. Patient volumes are rising, administrative burdens have grown, and there has been a marked shift towards private medical insurance and self-pay models across the UK and Europe. These changes have placed greater demands on practice management infrastructure, and exposed the limitations of systems that were not designed with modern care delivery in mind. The growth of self-pay in particular has introduced new commercial complexity for clinics, which must now manage patient financing, insurance verification and pricing transparency alongside their clinical operations. For smaller practices with limited IT resources, maintaining multiple disconnected platforms is both costly and time-consuming.

The Series C was led by Revaia, a European growth investor, with participation from Partech. Mercia Ventures and Octopus Ventures, both existing backers, also contributed to the round.

Semble has said the capital will be directed towards three areas. The first is expanding its reach into larger healthcare groups, which have more complex operational needs than the independent practices the company has historically served. The second is the development of artificial intelligence capabilities within the platform, with the aim of automating more of the administrative and coordination tasks that currently absorb clinical staff time. The third is consolidating its position in France, where the company has been building a presence alongside its UK operations.

Christoph Lippuner, chief executive and co-founder, said the healthcare sector had spent years attempting to solve systemic problems through point solutions that ultimately added to the complexity they were meant to reduce. "What healthcare organisations need is intelligent orchestration across the entire care journey," he stated. "The practices and groups that win over the next decade will be the ones that deliver the best patient experience end-to-end. This investment allows us to rapidly scale that vision across the UK and Europe."

The investment reflects a broader shift in how health technology investors are evaluating opportunities. Funding for isolated, single-function digital health tools has become harder to secure, while platforms that integrate multiple workflows and offer system-wide visibility have attracted greater interest. The logic is straightforward: a clinic that replaces several separate tools with one integrated platform reduces cost, reduces error, and generates more useful data about how care is being delivered. Semble is not alone in pursuing this model, but the size of this round suggests investors regard its position in the outpatient market as credible.

Whether the company can execute on its ambitions in France while simultaneously moving upmarket into larger enterprise clients will be the more testing question. Scaling into complex healthcare organisations requires a different sales cycle, different implementation support, and different product depth than serving independent practices. The £30 million gives Semble the resources to attempt both. How it prioritises will matter.

‍